ArticlePloS one2025
Utilization of varenicline among Kansas Medicaid enrollees.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSmoking prevalence among Medicaid beneficiaries is twice that of privately insured adults, yet effective smoking cessation treatments remain underutilized. Understanding varenicline use, the most effective smoking cessation medication, can inform efforts to improve tobacco treatment for Medicaid enrollees.
objectivesTo describe varenicline utilization among Kansas Medicaid (KanCare) enrollees from 2014-2021, including changes related to the FDA's December 2016 removal of the black box warning, and explore changes and demographic differences in its use. RESEARCH
designThis retrospective cohort study analyzed pharmacy claims data for varenicline utilization from January 1, 2014, to December 31, 2021. Tobacco use was estimated from the KanCare External Quality Review survey. SUBJECTS: The sample included 78,295 new adult enrollees (age 18+) with at least 11 months of continuous coverage. MEASURES: The primary outcome was varenicline utilization, defined as any pharmacy claim for the medication. Secondary outcomes included time to first prescription, completion of the 12-week treatment, and demographic differences in use.
resultsWith an estimated 30% smoking prevalence, only 12.7% of KanCare smokers received varenicline, and just 1.6% completed a full course of treatment. Among 78,295 new enrollees, 2,980 (3.8%) had one or more claims for varenicline, with the mean time from enrollment to first prescription being 1.5 years (SD 1.3). Utilization was higher among males (4.8%) than females (3.4%) and varied by race/ethnicity (Whites: 4.4%, Blacks: 2.7%, American Indians: 2.5%, Hispanics: 1.6%, p<0.0001). Among those who initiated treatment, only 13.5% (N=380) completed the recommended 12-week regimen.
conclusionsDespite the high smoking prevalence among KanCare beneficiaries, varenicline is underutilized, with significant demographic disparities. Men and non-Hispanic Whites were more likely to receive varenicline than women and other racial and ethnic groups, despite comparable or higher smoking rates among other subgroups. Medicaid programs must intensify efforts to provide equitable and effective tobacco treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.